Biomarker results from the KGOG3056/NIRVANA-R trial: Maintenance niraparib plus bevacizumab in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor.
Over the past few years, many clinical study administrators wanted to use the bring your own device (BYOD) model within their eCOA, but they were typically constrained by regulatory requirements or ...
To ensure that AI advances benefit everyone, scientific institutions must prioritize collaborative, mission-driven structures instead of chasing top talent with astronomical compensation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results